Approval · Notice of Compliance 27456 · 2022
3TC: Notice of Compliance 27456
Issued January 24, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27456
- Date
- January 24, 2022
- Company
- Viiv Healthcare UlcMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph (PM) with new information related to overdosage, transmission of HIV with antiretroviral therapy and lamivudine half-life.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| 3TC | Not yet assigned | — |
Medicinal ingredients
- LAMIVUDINE 150 MG per TAB
- LAMIVUDINE 300 MG per TAB
- LAMIVUDINE 10 MG per ML